Skip to content
The Policy VaultThe Policy Vault

KorlymCigna

Endogenous Cushing’s syndrome with type 2 diabetes mellitus or glucose intolerance in adults who have failed surgery or are not candidates for surgery

Preferred products

  • generic mifepristone tablets

Initial criteria

  • Patient meets the standard Cushing’s – Mifepristone Prior Authorization Policy criteria; AND
  • Patient has tried generic mifepristone tablets; AND
  • Patient cannot continue to use generic mifepristone tablets due to a formulation difference in the inactive ingredient(s) [e.g., difference in dyes, fillers, preservatives] which, per the prescriber, would result in a significant allergy or serious adverse reaction [documentation required]

Approval duration

1 year